Advocates haven’t given up on MDMA therapy getting FDA approval : Shots
![Advocates haven’t given up on MDMA therapy getting FDA approval : Shots Advocates haven’t given up on MDMA therapy getting FDA approval : Shots](https://npr.brightspotcdn.com/dims3/default/strip/false/crop/2122x1194+0+35/resize/1400/quality/100/format/jpeg/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F05%2F13%2Fc9b1b20a43dcbd6fa8c4155a548a%2Fgettyimages-1286653300.jpg)
Controversy has clouded efforts to get MDMA, or ecstasy, approved as a treatment for PTSD. But supporters haven’t given up and are lobbying for FDA approval.
Aitor Diago/Moment RF/Getty Images
hide caption
toggle caption
Aitor Diago/Moment RF/Getty Images
Working in the music industry, Rogers Masson traveled in plenty of circles where ecstasy made an appearance, but he was never interested in taking the drug himself.
He was equally skeptical when his wife first mentioned that a nearby clinic was combining therapy and MDMA, the active ingredient in ecstasy, to treat post-traumatic stress disorder.
“I blew it off as that’s a bunch of woo woo,” recalls Masson, who is 55 and suffered from PTSD for years after serving in the Army. “No way.”
So it’s with a touch of irony that Masson, who lives in North Carolina, now describes himself as a believer. He’s now joined a lobbying push by armed service veterans to bring the treatment into the mainstream.
It’s a pivotal moment: By August 11, the Food and Drug Administration is expected to make a landmark decision on whether to approve MDMA-assisted therapy for PTSD.
Supporters may face an uphill battle. In June, a panel of advisors to the FDA poked holes in the research from the drugmaker Lykos Therapeutics and voted overwhelmingly to reject the evidence.
The setback threatens to sink the drug’s chances, at least in the short term, and has led Lykos and its allies to redouble their efforts to build public support in the lead-up to the agency’s decision.
“I’m a complete newbie at this stuff,” says Masson, who’s planning to travel to Washington D.C. in the coming days to meet with lawmakers. “I feel the need to say something and hope that somebody will listen.”
![Rogers Masson, a musician and a veteran of the U.S. Army, says his PTSD symptoms improved after getting treatment with MDMA-assisted therapy as part of a clinical trial for the drug.](https://npr.brightspotcdn.com/dims3/default/strip/false/crop/6144x4096+0+0/resize/1100/quality/50/format/jpeg/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F03%2F0e%2F38b837c448ca9ce557883d533f9a%2Frogers-masson-3.jpeg)
Rogers Masson, a musician and a veteran of the U.S. Army, says his PTSD symptoms improved after getting treatment with MDMA-assisted therapy as part of a clinical trial for the drug.
Rogers Masson
hide caption
toggle caption
Rogers Masson
Veterans have emerged as some of the most visible advocates, arguing the drug fills a much-needed gap in effective treatments for PTSD.
In recents weeks, others have chimed in, too — some Democrat and Republican lawmakers, prominent figures in mental health and psychedelics, and even somebillionaires on social media.
“We are putting in more time and resources right now to make sure that the voices of the patients weren’t lost,” says Lykos CEO Amy Emerson. “The unmet need is clear.”
Can the FDA go against its advisers?
The downvote in June – not to mention controversy about the trials that spilled into full view during a public hearing — has put the FDA in a tough spot.
Heed its advisors’ recommendation and deny approval? Or greenlight the long-awaited decision on psychedelics?
History suggests the odds are stacked against approval.
Research shows FDA sides with its advisory committee in most circumstances. And when the agency does deviate, it’s usually in favor of taking a more cautious approach.
“Hardly ever do they go against a negative vote,” says Dr. Aaron Kesselheim, a professor at Harvard Medical School who specializes in FDA law.
However, the FDA isn’t immune to public pressure. There are times when the agency has moved ahead in spite of its advisors, particularly when patients have mounted an aggressive advocacy campaign.
“Historically, it absolutely does make a difference,” says Kesselheim, who was caught in the middle of a contentious decision on an Alzheimer’s drug.
“The FDA doesn’t operate in a vacuum. The staff read the same newspapers that you and I read,” he says.
The agency has a range of options: Lykos could be required to submit additional data, or even run a new clinical trial, which could push back the timeline considerably. Alternatively, approval could come with the requirements to do post-market research, plus tight restrictions on how the drug is administered.
“It’s so hard for me to speculate,” says Lykos’ Emerson. “But there is no stopping the work on this. We’ve put decades of time and resources into doing this research.”
Even those in favor of approval are hesitant to make any predictions.
“I would not hazard a guess,” says Harriet de Wit, a professor of psychiatry and behavioral neuroscience at the University of Chicago who has studied MDMA. “The FDA is faced with a very difficult decision that will set a precedent going forward. “
![A drugmaker seeks FDA approval for MDMA, or ecstasy, used as a treatment for PTSD in conjunction with therapy. Questions about the clinical trials cast doubt on its chances of FDA approval but supporters haven't given up.](https://npr.brightspotcdn.com/dims3/default/strip/false/crop/1024x728+0+0/resize/1100/quality/50/format/jpeg/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Fd9%2F8c%2F40403b184878b91b32cb25bc3776%2Fgettyimages-839738976.jpg)
A drugmaker seeks FDA approval for MDMA, or ecstasy, used as a treatment for PTSD in conjunction with therapy. Questions about the clinical trials cast doubt on its chances of FDA approval but supporters haven’t given up.
Travis Dove for The Washington Post/Getty Images
hide caption
toggle caption
Travis Dove for The Washington Post/Getty Images
Optimism about approval
Still, most in the field believe that approval for MDMA is not so much a matter of if, but when.
The treatment was granted breakthrough status, and FDA staff signed off on the trial design, although it became clear during the advisory meeting that certain recommendations were not followed.
Dr. George Greer, who signed a letter with de Wit and a handful of other researchers, was surprised by the unfavorable reception last month.
Still, he remains confident the drug will have its day.
“The benefits of MDMA for people with severe PTSD is virtually overwhelming,” says Greer, president of the Heffter Research Institute, a non-profit that funds psychedelic research.
Greer takes the long view, having used MDMA in therapy sessions at his San Francisco practice in the early ‘80s before the drug became a Schedule I controlled substance.
“It blocks the emotional fear response to a perceived threat,” says Greer. “It also provides the emotional energy to face those horrible trauma memories and come into a balance with them.”
The argument many U.S. veterans make in their lobbying for MDMA is that it works to heal the mental wounds of service, when other drugs like antidepressants don’t. Masson, who spent years trying conventional approaches through the Veterans Administration, says the treatment has rid him of nightmares that plagued him for three decades and dramatically “turned down the volume” on his symptoms.
The centerpiece of the Lykos’ application are two phase 3 clinical trials, which together enrolled about 200 people. The most recent one, published last year, showed just over 70% of participants no longer met the diagnostics criteria for PTSD after three therapy sessions with MDMA, compared to about 48% who had the same therapy but took a placebo.
Neuroscientist Matthew Baggott says those results are “compelling” and the risks were already well-understood — more than 1,500 people have been given MDMA in studies not sponsored by Lykos.
“I tend to think it’s more likely that it will be approved this time around,” says Baggott, who’s CEO of Tactogen, a company developing new drugs similar to MDMA.
Transformational or ‘fools’ gold’?
On the other side, some scientists are concerned about both the scientific rigor of Lykos’ MDMA research and serious allegations of misconduct and bias in the trials.
Lykos and investigators have steadfastly denied the latter
During June’s hearing, the FDA advisors raised a series of objections: That participants were not adequately blinded, meaning most could tell whether or not they received the drug. There were also concerns about missing data related to safety and a lack of evidence supporting the therapy protocol, to name a few.
“This is just shoddy research,” says Dr. Jeffrey Lieberman, a professor of psychiatry at Columbia University Medical Center who has written critically about the hype surrounding psychedelics.
Lieberman says he’s “bullish” about the therapeutic potential of psychedelics, but views the current enthusiasm as largely “speculative” because of weaknesses in the underlying data – including Lykos’ studies.
“We’re sort of at a Promethean moment where we have the potential to discover something that could be transformational. On the other hand, it could be fool’s gold,” he says, “I just don’t want us to squander the opportunity.”
However, many involved with psychedelic research were dismayed by the committee’s hang-up on issues like inadequate blinding of participants.
“I think that was overblown,” says Dr. Amy McGuire, director of the Center for Medical Ethics and Health Policy at Baylor College of Medicine.
She says it’s hard to tell how much the committee’s opposition was rooted in an “overly conservative” approach because of MDMA’s status as an illicit drug rather than legitimate concerns about lack of clinical benefit.
“I would just advocate for data-driven decision making that doesn’t exceptionalize psychedelics in ways that aren’t justified,” she says.
Controversy clouds the application
The wildcard in the FDA’s decision may be the ethical controversy over how Lykos’ ran its trials.
There is a well-documented instance of therapists having inappropriate physical contact with a patient, Meaghan Buisson, while she was under the influence of MDMA during the phase 2 trials. Sarah McNamee, a participant in the phase 3 trial, has described her own experience of “worsening symptoms” of suicidality and being inappropriately influenced by her therapist.
These issues and others were raised in a report from an institute that evaluates clinical research and in a petition to the FDA, calling for a public hearing because of allegations that bias influenced the results and some patients experienced adverse events that were not reported.
During the June advisory meeting, FDA staff alluded to an ongoing investigation, but a spokesperson told NPR the agency cannot comment on the details.
“I think any approval would require a full investigation of how Lykos conducted its trials,” says Neşe Devenot, who has helped lead opposition to the drug’s approval along with several others affiliated with the non-profit Psymposia, which describes itself as a watchdog for the psychedelic industry.
Since the hearing, online disputes have played out between the factions in favor of and against approval, with both questioning their underlying motives. For her part, Devenot says trial participants who’ve contacted her are afraid to come forward publicly because of the possible backlash.
The concerns and doubts about MDMA reflect issues with the history of the drugmaker and this trial, not necessarily the broader psychedelic industry, says Tactogen’s Baggott.
Lykos was incubated by a non-profit advocacy group, the Multidisciplinary Association for Psychedelic Studies, or MAPS, which started clinical research on MDMA two decades ago.
“You had this disorganized, activist organization that had this quixotic quest to make an illicit drug into a medicine, and slowly, over time, they became more professional,” he says.
The form of therapy used in MDMA sessions, which was developed by MAPS, has faced criticism that it can lead to abuses of power when patients are under the influence and vulnerable to suggestion.
“We cannot just use this sense of urgency to push forward a harmful model, which would ultimately backfire,” says Devenot, a senior lecturer in writing at Johns Hopkins, who studies psychedelics.
Even though MDMA goes hand-in-hand with psychotherapy, the agency doesn’t actually regulate that component, so ultimately “there’s no way to require that therapeutic approach be used” when treating patients, says Baggott.
McGuire, the Baylor College bioethicist, notes people are already seeking out the drug in the context of underground psychedelic retreats. Her research has tallied nearly 300 of them, many of which are advertising in the U.S., raising all kinds of safety issues.
“To me a harm reduction approach might be to have an approved medication that people can get administered under medical supervision,” she says.
By Baggot’s estimation, MDMA is unlikely to be a “blockbuster drug.” More than anything, he says, approval would be a big deal culturally and trigger investment in future psychedelics.
Rogers Masson, who benefitted from the treatment, wants to see MDMA approved, but he’s mindful of not overselling the drug.
“It’s just another tool. It’s not a magic pill,” he says, “There’s still a lot of self-work that has to go into it.”
Source link